Company Analysis
Sign in

Genmab A/S (GMAB)

Nasdaq: GMAB · Pharmaceutical Preparations · 1253 Copenhagen K, DK · filing with the SEC since 2008
Full chart Alerts Compare
Grade6.8
◀ Past 7.8● Present 6.9▶ Future 5.8
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

157 patents granted to the 6 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Genmab A/S’s names, not what it holds today.

Patents granted
157
156 utility, 1 reissue, 1976 to Dec 31, 2025
Granted in 2025
14
Against 16 in 2024 and 15 in 2023
Applications published
376
26 of them in 2025
Names they are printed under
6
its own name, a subsidiary
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals35
Biotechnology32
Analysis of biological materials1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name6 counted
GENMAB A/S its own name
named as the applicant on its applications, in DK. 29 more under the same name are not counted (printed in NL, printed in NE)
0 granted
187 published
Genmab A/S its own name
DK, as the owner printed on each patent. 1 more under the same name are not counted (printed in DE)
106 granted
70 published
Merus N.V. a subsidiary
NL, as the owner printed on each patent
43 granted
43 published
Merus N.V. a subsidiary
named as the applicant on its applications, in NL
0 granted
58 published
Merus B.V. a subsidiary
NL, as the owner printed on each patent
8 granted
14 published
GENMAB, INC. its own name
DK, as the owner printed on each patent
0 granted
4 published
Names not counted (1)
Tokyo, Japan
Most of its patents print JP; this name counts in NL. 3 granted and 0 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 23, 202512,503,509CLEC12AxCD3 bispecific antibodies and methods for the treatment of diseasePharmaceuticalsMerus N.V.
Nov 4, 202512,460,002CD3 binding moleculesBiotechnologyMerus N.V.
Oct 28, 202512,453,781Methods of treating cancer with a combination of an anti-VEGF antibody and an anti-tissue factor antibody-drug conjugatePharmaceuticalsGenmab A/S
Oct 7, 202512,435,154Bispecific antibodies against CD3 and CD20PharmaceuticalsGenmab A/S
Sep 23, 202512,421,319Binding agents that bind OX40 (CD134) and method of use thereof to treat diseasePharmaceuticalsGenmab A/S
Sep 16, 202512,415,859Methods of producing heterodimeric antibodiesBiotechnologyGenmab A/S
Aug 26, 202512,398,214Binding agents binding to EpCAM and CD137BiotechnologyGenmab A/S
Jul 8, 202512,351,650Antibodies binding to fibroblast activation protein alpha and death receptor 4PharmaceuticalsGenmab A/S
Jun 10, 202512,324,841Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugatePharmaceuticalsGenmab A/S
May 6, 202512,291,798Generation of binding moleculesBiotechnologyMerus N.V.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 18, 20252025/0382378CD38 ANTIBODIES AND USES THEREOFPharmaceuticalsGENMAB A/S
Dec 18, 20252025/0381289EGFR AND C-MET BISPECIFIC BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAMEPharmaceuticalsGENMAB A/S
Nov 6, 20252025/0340669HUMAN ANTIBODIES AGAINST TISSUE FACTOR AND METHODS OF USE THEREOFPharmaceuticalsGENMAB A/S
Nov 6, 20252025/0340647ANTIBODIESPharmaceuticalsGENMAB A/S
Nov 6, 20252025/0339523COMBINATION THERAPY FOR THE TREATMENT OF CANCERPharmaceuticalsMerus N.V.
Oct 30, 20252025/0333527ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND USES THEREOFBiotechnologyGENMAB A/S
Oct 30, 20252025/0333526ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND USES THEREOFBiotechnologyGENMAB A/S
Oct 23, 20252025/0325643BINDING AGENTS CAPABLE OF BINDING TO CD27 IN COMBINATION THERAPYPharmaceuticalsGENMAB A/S
Oct 2, 20252025/0305053NEW NRG1 FUSIONS, FUSION JUNCTIONS AND METHODS FOR DETECTING THEMBiotechnologyMerus N.V.
Oct 2, 20252025/0304689BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20PharmaceuticalsGENMAB A/S
What it applied for, 2024 to 2025: Pharmaceuticals 46 · Biotechnology 39 · Analysis of biological materials 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton GMAB · research, not advice